Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 9

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 9
---
(248) 
     -  
     - 
  
    Gain on revaluation of earnout and derivative liabilities 
     -  
     (4,870,000) 
     (320,117)
  
    Change in assets and liabilities: 

    Prepaid expenses and other current assets 
     (257,078) 
     (146,618) 
     142,687 
  
    Accounts payable 
     1,426,446  
     (360,204) 
     128,429 
  
    Accrued liabilities 
     (428,658) 
     1,526,821  
     (50,370)
  
    Operating lease liability 
     (644,476) 
     (520,454) 
     (121,589)
  
    Net cash used in operating activities 
     (12,273,817) 
     (10,738,473) 
     (637,400)

    Cash flows from investing activities: 

    Proceeds from sale of equity securities 
     500,000  
     -  
     - 
  
    Net cash provided by investing activities 
     500,000  
     -  
     - 

    Cash flows from financing activities: 

    Proceeds from issuance of Series A Preferred Stock, net of issuance costs 
     -  
     6,757,700  
     - 
  
    Advances from shareholder 
     -  
     13,731  
     - 
  
    Payment of sponsor loans 
     -  
     (19,715) 
     - 
  
    Proceeds from exercise of Series A Preferred Warrants 
     500,000  
     38,000  
     - 
  
    Proceeds from short-term borrowings, net 
     -  
     408,052  
     - 
  
    Payments for short term borrowings 
     -  
     (300,240) 
     - 
  
    Proceeds from share purchases and collection of stock subscription receivables under ELOC, net of issuance costs 
     3,704,123  
     4,139,190  
     - 
  
    Proceeds received from sale of Series B Preferred Stock 
     -